Federal and Florida regulators are moving quickly against certain kratom alkaloids. The DEA announced its intent to schedule products above specified 7-hydroxymitragynine limits and to prohibit MGM-15, MGM-16, and mitragynine pseudoindoxyl. Florida has already imposed related emergency requirements.
The DEA’s Proposed 7-OH Limits
One DEA notice would establish maximum 7-hydroxymitragynine levels for kratom products. Botanical kratom and extracts would be measured under different limits, creating a threshold model comparable in concept to the Delta-9 THC limit used in federal hemp law.
A product exceeding the applicable level could become a controlled substance under federal law. Manufacturers will therefore need reliable testing that distinguishes product types and accurately quantifies the active alkaloid.
MGM-15, MGM-16, and Pseudo Face Scheduling
A second notice targets MGM-15, MGM-16, and mitragynine pseudoindoxyl, sometimes called “pseudo.” The DEA characterizes these as synthetic alkaloids derived from botanical kratom and intends to place them in Schedule I.
The notices were issued in early July, with rules anticipated around August 5. The short timeline presents a serious inventory and packaging problem for businesses selling compounds that became popular during the previous 12 to 24 months.
Florida’s Emergency Kratom Rules Are Already Effective
Florida previously limited 7-OH concentrations and required disclosure on kratom labels. Its emergency rule requires labels to identify seven compounds and state quantitative testing information for each.
A label cannot simply say “non-detect.” If the amount is below what a laboratory can measure, the label must communicate the minimum detection capability. Many laboratories have not historically tested every required compound or reached the required sensitivity.
Florida also treats pseudo, MGM-15, and MGM-16 as adulterants. Products containing those compounds cannot lawfully be sold in the state under the emergency rule.
What Kratom Businesses Should Do Immediately
Inventory every formula and identify products containing targeted synthetic alkaloids. Determine which products exceed—or may exceed—the anticipated 7-OH thresholds.
Contact laboratories now to confirm testing capability, detection limits, and reporting formats. Botanical products may naturally contain small amounts of some alkaloids, so accurate quantitative results matter.
Review labels and order revised packaging before the federal deadline. Waiting for a final rule could leave a company unable to sell inventory while replacement labels take weeks to arrive.
A Broader Regulatory Convergence
The kratom and hemp industries are seeing a similar pattern: federal and state regulators are targeting compounds identified as intoxicating and moving them toward Schedule I treatment or strict concentration limits.
Businesses should treat the notices and Florida rule as immediate operational issues, not merely long-term policy debates.
This article supports a general understanding of current law and is not legal advice. Kratom businesses should seek counsel regarding scheduling, testing, labels, and inventory.
